Advanced Enzyme Technologies Limited — PPTs, 08-08-2026: Investor Presentation

Advanced Enzyme Technologies reported Q1 FY27 revenue of ₹189.8 Cr, up 2% YoY but down 7% QoQ. Profit (PAT) decreased 5% YoY to ₹38.6 Cr, while EBITDA fell 10% YoY to ₹51 Cr. Human Nutrition saw a 7% YoY dip, but Industrial Bio-processing surged 30% YoY to ₹30.6 Cr, driven by its food business. Specialized Manufacturing also posted strong 41% YoY growth, reaching ₹20 Cr. Europe and Asia (ex-India) were key growth regions, up 44% and 37% respectively.

The company's strategy focuses on broadening geographical presence, striking strategic partnerships, and pursuing inorganic growth through tech and client acquisitions. R&D remains a core investment for new enzymes, probiotics, and genetic engineering. Recent notable updates include commissioning a 510kW solar plant and establishing new labs for testing.

Management is prioritizing new products in Animal Nutrition and Probiotics for human/animal health. Bio-catalysis is advancing enzymatic solutions for API manufacturers. A key focus for Bio-processing is expanding Baking Solutions across Europe and the Americas.